Preponderant experimental evidence has demonstrated that pharmacological inhibition of sphingosine kinase isoforms (either sphingosine kinase 1 or 2) renders resistant colon cancer cells more responsive to both standard and targeted therapies. The gene discussed is SPHK1; the disease is malignant colon neoplasm.